Alzheimer’s is a disease that has no cure or effective way to prevent it. All the trials and studies that have been carried out up to now have as their main aim the achievement of a treatment capable of reducing cognitive damage of all people who suffer from this disease and thus improve their quality of life.
A new study carried out by the Clinical Hospital of Barcelona confirms the usefulness of a biomarker in blood to diagnose Alzheimer’s diseaser without the need for invasive tests.
To clinical trial participants, a total of 349 personasa blood sample was drawn for analyze the five plasma markers of cognitive impairment. Magazine Neurology has published results confirming that the Plasma ptau181 protein correlates with Alzheimer’s.
Marc Suárez-Calvet, neurologist from the Research Group on Physiology of Cognition and Alzheimer’s Prevention at IMIM-Hospital del Mar, celebrates that this study has been one of the most important advances in this field in recent years.
“The bottom line is that we really do have biomarkers in the blood that can be very useful in the Diagnosis of Alzheimer’s in daily clinical practicealthough it cannot yet be incorporated into daily life and cannot replace the standard test, lumbar puncture and cerebrospinal fluid analysis,” explains Suárez-Calvet.
Health Early detection of Alzheimer’s
Today, the main tests for the diagnosis of the disease are lumbar puncture or PET. However, the introduction of biomarkers can help improve the selection of patients who undergo these tests and an early detection of the disease.
Early detection of Alzheimer’s is essential to be able to intervene and improve the quality of life of all people who suffer from the disease. As the investigations progress, it is expected that they will develop new arrest techniques and tests that allow early diagnosis of the disease.
According to the authors of this latest study, we are getting closer to having a positive blood biomarker that indicates the possibility of a person suffering from Alzheimer’s.